<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36560641</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>26</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>25</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Reaching the Final Endgame for Constant Waves of COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2637</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v14122637</ELocationID><Abstract><AbstractText>Despite intramuscular vaccines saving millions of lives, constant devastating waves of SARS-CoV-2 infections continue. The elimination of COVID-19 is challenging, but necessary in order to avoid millions more people who would suffer from long COVID if we fail. Our paper describes rapidly advancing and innovative therapeutic strategies for the early stage of infection with COVID-19 so that tolerating continuing cycles of infection should be unnecessary in the future. These therapies include new vaccines with broader specificities, nasal therapies and antiviral drugs some targeting COVID-19 at the first stage of infection and preventing the virus entering the body in the first place. Our article describes the advantages and disadvantages of each of these therapeutic options which in various combinations could eventually prevent renewed waves of infection. Finally, important consideration is given to political, social and economic barriers that since 2020 hindered vaccine application and are likely to interfere again with any COVID-19 endgame.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ratcliffe</LastName><ForeName>Norman Arthur</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Biology Institute, Universidade Federal Fluminense, Niter&#xf3;i 24210-130, RJ, Brazil.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biosciences, Swansea University, Singleton Park, Swansea SA2 8PP, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castro</LastName><ForeName>Helena Carla</ForeName><Initials>HC</Initials><AffiliationInfo><Affiliation>Biology Institute, Universidade Federal Fluminense, Niter&#xf3;i 24210-130, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Marcelo Salabert</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Biology Institute, Universidade Federal Fluminense, Niter&#xf3;i 24210-130, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mello</LastName><ForeName>Cicero Brasileiro</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Biology Institute, Universidade Federal Fluminense, Niter&#xf3;i 24210-130, RJ, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dyson</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-0558-2666</Identifier><AffiliationInfo><Affiliation>Institute of Life Science, Medical School, Swansea University, Singleton Park, Swansea SA2 8PP, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 elimination</Keyword><Keyword MajorTopicYN="N">Omicron</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antiviral drugs</Keyword><Keyword MajorTopicYN="N">nasal therapies</Keyword><Keyword MajorTopicYN="N">new therapeutic options</Keyword><Keyword MajorTopicYN="N">political and social hindrances</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList><CoiStatement>The authors have declared that there are no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>23</Day><Hour>2</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36560641</ArticleId><ArticleId IdType="pmc">PMC9783511</ArticleId><ArticleId IdType="doi">10.3390/v14122637</ArticleId><ArticleId IdType="pii">v14122637</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organisation (WHO 2022)  [(accessed on 10 August 2022)].  Available online:  https://www.who.int/europe/news/item/19-07-2022-rapidly-escalating-COVID-19-cases-amid-reduced-virus-surveillance-forecasts-a-challenging-autumn-and-winter-in-the-who-european-region.</Citation></Reference><Reference><Citation>Bastian H. The Race to Reduce COVID-19 Transmission: An Update on 67 Intranasal &amp; 6 Oral Vaccines. Mar 20,  [(accessed on 10 July 2022)].  PLOS BLOGS March 20 (2022) Available online:  https://absolutelymaybe.plos.org/2022/03/30/the-race-to-reduce-COVID-19-transmission-an-update-on-66-intranasal-6-oral-vaccines/</Citation></Reference><Reference><Citation>Vitiello A., Ferrara F., Auti A.M., Di Domenico M., Boccellino M. Advances in the Omicron variant development. J. Intern. Med. 2022;292:81&#x2013;90. doi: 10.1111/joim.13478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13478</ArticleId><ArticleId IdType="pmc">PMC9115048</ArticleId><ArticleId IdType="pubmed">35289434</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagesha S.N., Ramesh B.N., Pradeep C., Shashidhara K.S., Ramakrishnappa T., Krishnaprasad B.T., Jnanashree S.M., Manohar M., Arunkumar N., Patel D., et al. SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study. Mater. Today Proc. 2021;49:904&#x2013;912. doi: 10.1016/j.matpr.2021.07.163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matpr.2021.07.163</ArticleId><ArticleId IdType="pmc">PMC8279943</ArticleId><ArticleId IdType="pubmed">34307057</ArticleId></ArticleIdList></Reference><Reference><Citation>Balmforth D., Swales J.A., Silpa L., Dunton A., Davies K.E., Davies S.G., Kamath A., Gupta J., Gupta S., Masood M., et al. Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial. J. Clin. Virol. 2022;155:105248. doi: 10.1016/j.jcv.2022.105248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2022.105248</ArticleId><ArticleId IdType="pmc">PMC9313533</ArticleId><ArticleId IdType="pubmed">35952426</ArticleId></ArticleIdList></Reference><Reference><Citation>Muzio L.L., Spirito F. Nasal vaccine or monoclonal therapy: Which is winning weapon against SARS-CoV-2 variants in 2022? J. Glob. Health. 2022;12:03023. doi: 10.7189/jogh.12.03023.</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.12.03023</ArticleId><ArticleId IdType="pmc">PMC9107288</ArticleId><ArticleId IdType="pubmed">35567581</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami N., Hayden R., Hills T., Al-Samkari H., Casey J., Del Sorbo L., Lawler P.R., Sise M.E., Leaf D.E. Therapeutic advances in COVID-19. Nat. Rev. Nephrol. 2022;17:1&#x2013;15. doi: 10.1038/s41581-022-00642-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-022-00642-4</ArticleId><ArticleId IdType="pmc">PMC9574806</ArticleId><ArticleId IdType="pubmed">36253508</ArticleId></ArticleIdList></Reference><Reference><Citation>Nitin P., Nandhakumar R., Vidhya B., Rajesh S., Sakunthala A. COVID-19: Invasion, pathogenesis and possible cure&#x2014;A review. J. Virol. Methods. 2022;300:114434. doi: 10.1016/j.jviromet.2021.114434.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jviromet.2021.114434</ArticleId><ArticleId IdType="pmc">PMC8669942</ArticleId><ArticleId IdType="pubmed">34919978</ArticleId></ArticleIdList></Reference><Reference><Citation>Rekha M.S., Kumar G.S., Meghana G., Balaji A., Kumar M.S. COVID 19: A Comprehensive Review. Int. J. Pharm. Sci. Rev. Res. 2022;72:133&#x2013;149.</Citation></Reference><Reference><Citation>Hui K.P., Ho J.C., Cheung M.C., Ng K.C., Ching R.H., Lai K.L., Kam T.T., Gu H., Sit K.Y., Hsin M.K.Y., et al. SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo. Nature. 2022;603:715&#x2013;720. doi: 10.1038/s41586-022-04479-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04479-6</ArticleId><ArticleId IdType="pubmed">35104836</ArticleId></ArticleIdList></Reference><Reference><Citation>Americo J.L., Cotter C.A., Earl P.L., Liu R., Moss B. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection. Proc. Natl. Acad. Sci. USA. 2022;119:e2202069119. doi: 10.1073/pnas.2202069119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2202069119</ArticleId><ArticleId IdType="pmc">PMC9214525</ArticleId><ArticleId IdType="pubmed">35679343</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratcliffe N.A., Castro H.C., Paix&#xe3;o I.C., Evangelho V.G.O., Azambuja P., Mello C.B. Nasal therapy&#x2014;The missing link in optimising strategies to improve prevention and treatment of COVID-19. PLoS Pathog. 2021;17:e1010079. doi: 10.1371/journal.ppat.1010079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010079</ArticleId><ArticleId IdType="pmc">PMC8612505</ArticleId><ArticleId IdType="pubmed">34818380</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson P.C., Liew D.F.L., Tanner H.L., Grainger J.R., Dwek R.A., Reisler R.B., Steinman L., Feldmann M., Ho L.-P., Hussell T., et al. COVID-19 therapeutics: Challenges and directions for the future. Proc. Natl. Acad. Sci. USA. 2022;119:e2119893119. doi: 10.1073/pnas.2119893119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2119893119</ArticleId><ArticleId IdType="pmc">PMC9169797</ArticleId><ArticleId IdType="pubmed">35385354</ArticleId></ArticleIdList></Reference><Reference><Citation>Alu A., Chen L., Lei H., Wei Y., Tian X., Wei X. Intranasal COVID-19 vaccines: From bench to bed. Lancet. 2022;76:103841. doi: 10.1016/j.ebiom.2022.103841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103841</ArticleId><ArticleId IdType="pmc">PMC8785603</ArticleId><ArticleId IdType="pubmed">35085851</ArticleId></ArticleIdList></Reference><Reference><Citation>Akinbolade S., Coughlan D., Fairbairn R., McConkey G., Powell H., Ogunbayo D., Craig D. Combination therapies for COVID-19: An overview of the clinical trials landscape. Br. J. Clin. Pharmacol. 2022;88:1590&#x2013;1597. doi: 10.1111/bcp.15089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15089</ArticleId><ArticleId IdType="pmc">PMC8652622</ArticleId><ArticleId IdType="pubmed">34558094</ArticleId></ArticleIdList></Reference><Reference><Citation>Barakat A., Mostafa A., Ali M., Al-Majid A.M., Domingo L.R., Kutkat O., Moatasim Y., Zia K., Ul-Haq Z., Elshaier Y.A.M.M. Design, synthesis and in vitro evaluation of spirooxindole-based phenylsulfonyl moiety as a candidate anti-SAR-CoV-2 and MERS-CoV-2 with the Implementation of combination studies. Int. J. Mol. Sci. 2022;23:11861. doi: 10.3390/ijms231911861.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms231911861</ArticleId><ArticleId IdType="pmc">PMC9569468</ArticleId><ArticleId IdType="pubmed">36233160</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolgin E. The race for antiviral drugs to beat COVID- and the next pandemic. Nature. 2021;592:340&#x2013;343. doi: 10.1038/d41586-021-00958-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-00958-4</ArticleId><ArticleId IdType="pubmed">33854246</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratcliffe N.A., Castro H.C., Paix&#xe3;o I.C., Mello C.B. COVID-19: Innovative antiviral drugs required for long-term prevention and control of coronavirus diseases. Curr. Med. Chem. 2021;28:3554&#x2013;3567. doi: 10.2174/0929867327666201027152400.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867327666201027152400</ArticleId><ArticleId IdType="pubmed">33109030</ArticleId></ArticleIdList></Reference><Reference><Citation>Sidik S.M. The hunt for drugs for mild COVID: Scientists seek to treat those at lower risk. Nat. NEWS. 2022 doi: 10.1038/d41586-022-01923-5. Epub ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-01923-5</ArticleId><ArticleId IdType="pubmed">35851152</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization (WHO 2022)  [(accessed on 11 August 2022)].  Available online:  https://www.who.int/news/item/17-06-2022-interim-statement-on-decision-making-considerations-for-the-use-of-variant-updated-COVID-19-vaccines.</Citation></Reference><Reference><Citation>GOV UK (Government UK)  First Bivalent COVID-19 Booster Vaccine Approved by UK Medicines Regulator. News Release, 15 August 2022.  [(accessed on 8 September 2022)]; Available online:  https://www.gov.uk/government/news/first-bivalent-covid-19-booster-vaccine-approved-by-uk-medicines-regulator.</Citation></Reference><Reference><Citation>Hewins B., Rahman M., Bermejo-Martin J.F., Kelvin A.A., Richardson C.D., Rubino S., Kumar A., Ndishimye P., Ostadgavahi A.T., Mahmud-Al-Rafat A., et al. Alpha, beta, delta, omicron, and SARS-CoV-2 breakthrough cases: Defining immunological mechanisms for vaccine waning and vaccine-variant mismatch. Front. Virol. 2022;2:849936. doi: 10.3389/fviro.2022.849936.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fviro.2022.849936</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolgin E. Pan-coronavirus vaccine pipeline takes form. Nat. Rev. Drug Discov. 2022;21:324&#x2013;326. doi: 10.1038/d41573-022-00074-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41573-022-00074-6</ArticleId><ArticleId IdType="pubmed">35440811</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K.-H., Li Z., Bhatnagar N., Subbiah J., Park B.R., Shin C.H., Pushko P., Wang B.-Z., Kang S.-M. Universal protection against influenza viruses by multi-subtype neuraminidase and M2 ectodomain virus-like particle. PLoS Pathog. 2022;18:e1010755. doi: 10.1371/journal.ppat.1010755.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010755</ArticleId><ArticleId IdType="pmc">PMC9409530</ArticleId><ArticleId IdType="pubmed">36006890</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds C.J., Pade C., Gibbons J.M., Otter A.D., Lin K.-M., Sandoval D.M., Pieper F.P., Butler D.K., Liu S., Joy G., et al. Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure. Science. 2022;377:eabq1841. doi: 10.1126/science.abq1841.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abq1841</ArticleId><ArticleId IdType="pmc">PMC9210451</ArticleId><ArticleId IdType="pubmed">35699621</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiege J.K., Block K.E., Pierson M.J., Nanda H., Shepherd F.K., Mickelson C.K., Stolley J.M., Matchett W.E., Wijeyesinghe S., Meyerholz D.K., et al. Mice with diverse microbial exposure histories as a model for preclinical vaccine testing. Cell Host Microbe. 2021;29:1815&#x2013;1827.e6. doi: 10.1016/j.chom.2021.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.10.001</ArticleId><ArticleId IdType="pmc">PMC8665115</ArticleId><ArticleId IdType="pubmed">34731647</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvalho T. Intranasal COVID-19 vaccine fails to induce mucosal immunity. Nat Med. 2022 doi: 10.1038/d41591-022-00106-z. Epub ahead of print .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41591-022-00106-z</ArticleId><ArticleId IdType="pubmed">36329319</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu J., Jain S., Sha J., Batra H., Ananthaswamy N., Kilgore P.B., Hendrix E.K., Hosakote Y.M., Wu X., Olano J.P., et al. A bacteriophage-based, highly efficacious, needle- and adjuvant-free, mucosal COVID-19 vaccine. mBio. 2022;13:e0182222. doi: 10.1128/mbio.01822-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.01822-22</ArticleId><ArticleId IdType="pmc">PMC9426593</ArticleId><ArticleId IdType="pubmed">35900097</ArticleId></ArticleIdList></Reference><Reference><Citation>Waltz E. How nasal-spray vaccines could change the pandemic. Nature. 2022;609:240&#x2013;242. doi: 10.1038/d41586-022-02824-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-02824-3</ArticleId><ArticleId IdType="pubmed">36068305</ArticleId></ArticleIdList></Reference><Reference><Citation>Farahani M., Niknam Z., Amirabad L.M., Amiri-Dashatan N., Koushki M., Nemati M., Pouya F.D., Rezaei-Tavirani M., Rasmi Y., Tayebi L. Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets. Biomed. Pharmacother. 2022;145:112420. doi: 10.1016/j.biopha.2021.112420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biopha.2021.112420</ArticleId><ArticleId IdType="pmc">PMC8585639</ArticleId><ArticleId IdType="pubmed">34801852</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapira T., Monreal I.A., Dion S.P. A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic. Nature. 2022;605:340&#x2013;348. doi: 10.1038/s41586-022-04661-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04661-w</ArticleId><ArticleId IdType="pmc">PMC9095466</ArticleId><ArticleId IdType="pubmed">35344983</ArticleId></ArticleIdList></Reference><Reference><Citation>Arimori T., Ikemura N., Okamoto T., Takagi J., Standley D.M., Hoshino A. Engineering ACE2 decoy receptors to combat viral escapability. Trends Pharmacol. Sci. 2022;43:838&#x2013;851. doi: 10.1016/j.tips.2022.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2022.06.011</ArticleId><ArticleId IdType="pmc">PMC9312672</ArticleId><ArticleId IdType="pubmed">35902282</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Sun L., Ullah I., Beaudoin-Bussi&#xe8;res G., Anand S.P., Hederman A.P., Tolbert W.D., Sherburn R., Nguyen D.N., Marchitto L., et al. Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities. Sci. Adv. 2022;8:eabn4188. doi: 10.1126/sciadv.abn4188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abn4188</ArticleId><ArticleId IdType="pmc">PMC9278865</ArticleId><ArticleId IdType="pubmed">35857504</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallentin L., Lindb&#xe4;ck J., Eriksson N., Hijazi Z., Eikelboom J.W., Ezekowitz M.D., Granger C.B., Lopes R.D., Yusuf S., Oldgren J., et al. Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. Eur. Heart J. 2020;41:4037&#x2013;4046. doi: 10.1093/eurheartj/ehaa697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehaa697</ArticleId><ArticleId IdType="pmc">PMC7543499</ArticleId><ArticleId IdType="pubmed">32984892</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmah L., Abarikwu S.O., Arero A.G., Essouma M., Jibril A.T., Fal A., Flisiak R., Makuku R., Marquez L., Mohamed K., et al. Oral antiviral treatments for COVID-19: Opportunities and challenges. Pharmacol. Rep. 2022:1&#x2013;24. doi: 10.1007/s43440-022-00388-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-022-00388-7</ArticleId><ArticleId IdType="pmc">PMC9309032</ArticleId><ArticleId IdType="pubmed">35871712</ArticleId></ArticleIdList></Reference><Reference><Citation>Tandon M., Wu W., Moore K., Winchester S., Tu Y.-P., Miller C., Kodgule R., Pendse A., Rangwala S., Joshi S. SARS-CoV-2 accelerated clearance using a novel nitric oxide nasal spray (NONS) treatment: A randomized trial. Lancet Reg. Health Southeast Asia. 2022;3:100036. doi: 10.1016/j.lansea.2022.100036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lansea.2022.100036</ArticleId><ArticleId IdType="pmc">PMC9239922</ArticleId><ArticleId IdType="pubmed">35784831</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajendran R., Chathambath A., Al-Sehemi A.G., Pannipara M., Unnikrishnan M.K., Aleya L., Raghavan R.P., Mathew B. Critical role of nitric oxide in impeding COVID-19 transmission and prevention: A promising possibility. Environ. Sci. Pollut. Res. Int. 2022;29:38657&#x2013;38672. doi: 10.1007/s11356-022-19148-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11356-022-19148-4</ArticleId><ArticleId IdType="pmc">PMC8902850</ArticleId><ArticleId IdType="pubmed">35258738</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisi F., Zelikin A.N., Chandrawati R. Nitric oxide to fight viral infections. Adv. Sci. 2021;8:2003895. doi: 10.1002/advs.202003895.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/advs.202003895</ArticleId><ArticleId IdType="pmc">PMC7995026</ArticleId><ArticleId IdType="pubmed">33850691</ArticleId></ArticleIdList></Reference><Reference><Citation>NHS Inform.  [(accessed on 30 October 2022)].  Available online:  https://www.nhsinform.scot/covid-19-vaccine/side-effects-of-the-coronavirus-vaccines.</Citation></Reference><Reference><Citation>Food and Drug Administration (FDA)  Coronavirus (COVID-19) News Update February 11 2022.  [(accessed on 3 June 2022)]; Available online:  https://www.fda.gov/news-events/press-announcements/coronavirus-COVID-19-update-fda-authorizes-new-monoclonal-antibody-treatment-COVID-19-retains.</Citation></Reference><Reference><Citation>Gil-Sierra M.D., Brice&#xf1;o-Casado M.D.P., Rey E.J.A.-D., S&#xe1;nchez-Hidalgo M. Efficacy of early use of remdesivir: A systematic review of subgroup analysis. Rev. Esp. Quimioter. 2022;35:249&#x2013;259. doi: 10.37201/req/154.2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.37201/req/154.2021</ArticleId><ArticleId IdType="pmc">PMC9134888</ArticleId><ArticleId IdType="pubmed">35294145</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee T.C., Murthy S., Del Corpo O., Sen&#xe9;cal J., Butler-Laporte G., Sohani Z.N., Brophy J.M., McDonald E.G. Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis. Clin Microbiol Infect. 2022;28:1203&#x2013;1210. doi: 10.1016/j.cmi.2022.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.04.018</ArticleId><ArticleId IdType="pmc">PMC9117160</ArticleId><ArticleId IdType="pubmed">35598856</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitre T., Van Alstine R., Chick G., Leung G., Mikhail D., Cusano E., Khalid F., Zeraatkar D. Antiviral drug treatment for non-severe COVID-19: A systematic review and network meta-analysis. Can. Med. Assoc. J. 2022;194:E969&#x2013;E980. doi: 10.1503/cmaj.220471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.220471</ArticleId><ArticleId IdType="pmc">PMC9328465</ArticleId><ArticleId IdType="pubmed">35878897</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbel R., Sagy Y.W., Hoshen M., Battat E., Lavie G., Sergienko R., Friger M., Peretz A., Yaron S., Serby D., et al. Oral Nirmatrelvir and severe COVID-19 outcomes during the omicron surge. Res. Sq. 2022 doi: 10.21203/rs.3.rs-1705061/v1. Preprint .</Citation><ArticleIdList><ArticleId IdType="doi">10.21203/rs.3.rs-1705061/v1</ArticleId><ArticleId IdType="pmc">PMC9454652</ArticleId><ArticleId IdType="pubmed">36001529</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health (NIH)  Antiviral Drugs That Are Approved, Authorized, or Under Evaluation for the Treatment of COVID-19. 8 August 2022.  [(accessed on 14 August 2022)]; Available online:  https://files.covid19treatmentguidelines.nih.gov/guidelines/section/section_36.pdf.</Citation></Reference><Reference><Citation>Ledford H. Hundreds of COVID trials could provide a deluge of new drugs. Nature. 2022;603:25&#x2013;27. doi: 10.1038/d41586-022-00562-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-00562-0</ArticleId><ArticleId IdType="pubmed">35233098</ArticleId></ArticleIdList></Reference><Reference><Citation>Foletto V.S., da Rosa T.F., Serafin M.B., H&#xf6;rner R. Selective serotonin reuptake inhibitor (SSRI) antidepressants reduce COVID 19 infection: Prospects for use. Eur. J. Clin. Pharmacol. 2022;78:1601&#x2013;1611. doi: 10.1007/s00228-022-03372-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-022-03372-5</ArticleId><ArticleId IdType="pmc">PMC9360648</ArticleId><ArticleId IdType="pubmed">35943535</ArticleId></ArticleIdList></Reference><Reference><Citation>The National Institutes, COVID-19, &#x201c;Treatment Guidelines of Health&#x201d;.  [(accessed on 5 July 2022)]; Available online:  https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/</Citation></Reference><Reference><Citation>The World Health Organisation (WHO)  Living Guideline.  [(accessed on 14 August 2022)].  Available online:  https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-therapeutics-2022.4.</Citation></Reference><Reference><Citation>Kamp J. COVID-19 Is Still Killing Hundreds of Americans Daily. Wall Street Journal. Sep 11, 2022.  [(accessed on 14 August 2022)].  Available online:  https://www.wsj.com/articles/covid-19-is-still-killing-hundreds-of-americans-daily-11662888600.</Citation></Reference><Reference><Citation>Goda G.S., Soltas E.J. The impacts of COVID-19 illnesses on workers. NBER. 2022:30435. doi: 10.3386/w30435.</Citation><ArticleIdList><ArticleId IdType="doi">10.3386/w30435</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC)  Long COVID or Post-COVID Conditions.  [(accessed on 5 July 2022)]; Available online:  https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.</Citation></Reference><Reference><Citation>Taquet M., Sillett R., Zhu L., Mendel J., Camplisson I., Dercon Q., Harrison P.J. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: An analysis of 2-year retrospective cohort studies including 1284437 patients. Lancet Psychiatry. 2022;9:815&#x2013;827. doi: 10.1016/S2215-0366(22)00260-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(22)00260-7</ArticleId><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>Topol E.J., Iwasaki A. Operation nasal vaccine-lightning speed to counter COVID-19. Sci. Immunol. 2022;7:eadd9947. doi: 10.1126/sciimmunol.add9947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.add9947</ArticleId><ArticleId IdType="pubmed">35862488</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang K., Wang C., Kreutzberger A.J.B., Ojha R., Kuivanen S., Couoh-Cardel S., Muratcioglu S., Eisen T.J., White K.I., Held R.G., et al. Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the pre-hairpin intermediate of the spike protein. bioRxiv. 2022;119:e2210990119. doi: 10.1101/2022.08.11.503553.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.11.503553</ArticleId><ArticleId IdType="pmc">PMC9546559</ArticleId><ArticleId IdType="pubmed">36122200</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson O.J., Barnsley G., Toor J., Hogan A.B., Winskill P., Ghani A.C. Global impact of the first year of COVID-19 vaccination: A mathematical modelling study. Lancet Infect Dis. 2022;22:1293&#x2013;1302. doi: 10.1016/S1473-3099(22)00320-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00320-6</ArticleId><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organisation WHO releases global COVID-19 vaccination strategy update to reach unprotected. Saudi Med. J. 2022;43:976.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9749664</ArticleId><ArticleId IdType="pubmed">35964953</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazer D., Uslu A., Qu H., Santillana M., Perlis R., Ognyanova K., Baum M., Druckman J., Trujillo K.L., Safarpour A., et al. The COVID States Project#90: Utilization Rates of Antivirals for COVID-19. OSF Preprints; Charlottesville, VA, USA: 2022.</Citation></Reference><Reference><Citation>Chaudhary S., Natt B., Bime C., Knox K.S., Glassberg M.K. Antifibrotics in COVID-19 lung disease: Let us stay focused. Front Med. (Lausanne) 2020;7:539. doi: 10.3389/fmed.2020.00539.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.00539</ArticleId><ArticleId IdType="pmc">PMC7531602</ArticleId><ArticleId IdType="pubmed">33072773</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutenbrunner C., Nugraha B., Martin L.T. Phase-adapted rehabilitation for acute coronavirus disease-19 patients and patient with long-term sequelae of coronavirus disease-19. Am. J. Phys. Med. Rehabil. 2021;100:533&#x2013;538. doi: 10.1097/PHM.0000000000001762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PHM.0000000000001762</ArticleId><ArticleId IdType="pubmed">33901039</ArticleId></ArticleIdList></Reference><Reference><Citation>Statista  COVID-19, Pneumonia, and Influenza Deaths Reported U.S. 2022.  [(accessed on 13 September 2022)].  Available online:  https://www.statista.com/statistics/1113051/number-reported-deaths-from-COVID-pneumonia-and-flu-us/</Citation></Reference><Reference><Citation>Maragakis L.L. COVID-19 vs. Flu. 2022.  [(accessed on 20 August 2022)].  Available online:  https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-disease-2019-vs-the-flu.</Citation></Reference><Reference><Citation>Mohammed M. The New COVID Subvariant BA.4.6 Is Spreading. Here&#x2019;s What We Know.  [(accessed on 15 September 2022)].  Available online:  https://www.sciencealert.com/the-new-COVID-subvariant-ba-4-6-is-spreading-heres-what-we-know.</Citation></Reference><Reference><Citation>Cohen J. Making broader coronavirus vaccines is a struggle. Science. 2022;377:566&#x2013;567. doi: 10.1126/science.ade2363.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.ade2363</ArticleId><ArticleId IdType="pubmed">35926025</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu C., Wang A., Honnen W., Pinter A., Weston W.K., Harness J.A., Narayanan A., Chang T.L. Brilacidin, a non-peptide defensin-mimetic molecule, inhibits SARS-CoV-2 infection by blocking viral entry. EC Microbiol. 2022;18:1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9186380</ArticleId><ArticleId IdType="pubmed">35695877</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellarnau A., Heery G.P., Seta A., Luscombe C.A., Kinghorn G.R., Button P., McCloud P., Paull J.R.A. Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial. Sci. Rep. 2022;12:10210. doi: 10.1038/s41598-022-14601-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-14601-3</ArticleId><ArticleId IdType="pmc">PMC9204674</ArticleId><ArticleId IdType="pubmed">35715644</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachs J.D., Karim S.S.A., Aknin L., Allen J., Brosb&#xf8;l K., Colombo F., Barron G.C., Espinosa M.F., Gaspar V., Gaviria A., et al. The Lancet Commission on lessons for the future from the COVID-19 pandemic. Lancet. 2022;400:1224&#x2013;1280. doi: 10.1016/S0140-6736(22)01585-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01585-9</ArticleId><ArticleId IdType="pmc">PMC9539542</ArticleId><ArticleId IdType="pubmed">36115368</ArticleId></ArticleIdList></Reference><Reference><Citation>Looi M.-K. The BMJ Interview: WHO chief scientist optimistic for a pan-coronavirus vaccine in two years. BMJ. 2022;377:o1003. doi: 10.1136/bmj.o1003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.o1003</ArticleId><ArticleId IdType="pubmed">35473706</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>